Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Scandion Oncology
0,168 SEK −1,18%Ole ensimmäinen seuraaja
Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.
Liikevaihto
-
EBIT %
-
P/E -luku
-
Osinkotuotto %
-
Tavoitehinta
-
Suositus
-
Päivitetty
-
First North Stockholm
SCOL
Päivän matalin / päivän korkein hinta
0,165 / 0,173
SEK
Markkina-arvo
38,96 milj. SEK
Vaihto
189,45 t. SEK
Vaihtomäärä, kappaletta
1,1 milj.
Viimeisimmät videot
Pörssikalenteri
Osavuosikatsaus
29.08.2024
Osavuosikatsaus
27.11.2024
Vuosikatsaus
28.02.2025
NäytäKaikki sisältötyypit
Scandion Oncology board member Michel Ducreux steps down, joins advisory board
SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Scandion announces change of Certified Adviser to Vator Securities
SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE
Redeye: Scandion Oncology Q1 2024 - Funding for CORIST part 3 extension
SCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE
![Scandion Oncology, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/c06ebf17-358d-46c1-99b3-80945024eee0.png)
Scandion Oncology, Audiocast with teleconference, Q1, 2024
Scandion Oncology – Interim Report Q1 2024
Invitation to Scandion Oncology webcast and conference call May 22, 2024
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
Scandion Oncology to Host R&D Update May 15
Scandion Oncology – Notice convening the Annual General Meeting
SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival
Scandion Oncology - Annual Report 2023
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial
Redeye: Scandion Oncology Q4 2023 - Striving towards randomised controlled data
![Scandion Oncology, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/07127bad-fc39-49dd-8a39-998bae38ebc7.png)